Clinical Data ESC 2026: Evolocumab explores new frontiers in CV disease prevention Pharmaceutical TechnologyThe benefits of intensive LDL-C lowering with Repatha (evolocumab) may extend beyond cardiovascular event prevention to reducing mortality.CardiovascularRead full story pharminent August 31, 2026 (Last updated: September 1, 2026) Pharmaceutical Technology The benefits of intensive LDL-C lowering with Repatha (evolocumab) may extend beyond cardiovascular event prevention to reducing mortality. Cardiovascular Read full story Post navigation Previous: Acquisitive Lilly offers $2.88bn for Merida BioNext: FDA clears Takeda, Protagonist’s first-in-class PV drug Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026